Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial

ENGLEWOOD, Colo., Dec. 1, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study.

The seven (7) patient 'open label' phase of the 47 patient STRUT study was performed to assure that multiple injections of Ampion™ were safe.  Each patient received three 4ml intra-articular injections of Ampion™, one at baseline, the second at 2 weeks and the third at 4 weeks. There were no drug related serious adverse events reported during the first 20 weeks of this current trial; the further results of this open label phase are as follows:

• WOMAC A: The primary endpoint, WOMAC A pain score, improved by 91.2% from baseline to 20 weeks. The WOMAC A mean (SD) significantly improved from 2.27 (0.59) at baseline, to 0.20 (0.23) at week 20, mean difference (95% CI) -2.03 (-2.83,-1.23), p=0.001. 
• WOMAC B: The secondary endpoint measurement of stiffness, also improved significantly by 87% from baseline at week 20 from mean (SD) of 2.75 (0.82) to 0.36 (0.48), mean difference (95% CI) –2.33 (-3.51,-1.15) p=0.004.
• WOMAC C: The secondary endpoint of a validated measure of simple daily physical functions improved by 91.3% from baseline at week 20 .This improvement was statistically significant, going from 2.32 (0.60) at baseline to 0.20 (0.34) at week 20; mean (95% CI) improvement of –2.09 (-2.96,-1.21), p=0.002.

About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements:
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact:
April Ramirez
Operations Coordinator
Ampio Pharmaceuticals, Inc.
373 Inverness Parkway, Englewood, CO 80112
Direct: (720) 437-6524

Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-announces-results-of-the-open-label-portion-of-the-multiple-intra-articular-injections-strut-study-of-ampion-in-patients-with-osteoarthritis-of-the-knee-at-week-twenty-of-the-trial-300002358.html

SOURCE Ampio Pharmaceuticals, Inc.